Genomic

Dataset Information

0

Genetic Analysis of Tumor Samples


ABSTRACT:

Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including production of IFN-γ, which is a critical cytokine for host immune responses. However, the role of IFN-γ signaling in tumor cells in the setting of anti-CTLA-4 therapy remains unknown. Here we demonstrate that, based upon exome sequencing data, patients identified as non-responders to anti-CTLA-4 (ipilimumab) harbor a much higher genomic defects in the IFN-γ pathway genes than melanoma patients who had clinical response to ipilimumab therapy.

PROVIDER: phs001257 | dbGaP |

SECONDARY ACCESSION(S): PRJNA357320PRJNA357321

REPOSITORIES: dbGaP

Dataset's files

Source:
Action DRS
GapExchange_phs001257.v1.p1.xml Xml
dbGaPEx2.1.5.xsd Other
Study_Report.phs001257.Anti_CTLA_4.v1.p1.MULTI.pdf Pdf
manifest_phs001257.Anti_CTLA_4.v1.p1.c1.DS-M-PUB-NPU.pdf Pdf
datadict_v2.xsl Other
Items per page:
1 - 5 of 30

Similar Datasets

2024-08-01 | GSE273718 | GEO
2024-07-30 | GSE272993 | GEO
2024-07-30 | GSE272735 | GEO
2024-07-30 | GSE272734 | GEO
2022-01-10 | PXD021748 | Pride
2022-04-21 | PXD033340 | Pride
| phs001493 | dbGaP
2017-06-02 | GSE99552 | GEO
2018-10-24 | GSE121694 | GEO
2014-12-12 | E-GEOD-64102 | biostudies-arrayexpress